Emgality

USDailyMed:Galcanezumab N02CD02(WHO) CA:℞-onlyUS:℞-onlyEU:Rx-onlyIn general: ℞ (Prescription only) 1578199-75-3 346930785 DB14042 none 55KHL3P693 D10936 Galcanezumab,sold under the brand nameEmgality, is ahumanizedmonoclonal antibodyused for the prevention ofmigraine.It is also used for the treatment ofcluster headaches. A substance calledcalcitonin gene-related peptide(CGRP) has been shown to be involved in the development of migraine by widening blood vessels in the brain.Galcanezumab is a monoclonal antibody (a type of protein) designed to attach to and block CGRP, thereby helping blood vessels to return to their normal size.This will stop the symptoms of migraine.Galcanezumab is generally delivered through self-injections.Common side effects includeinjection site reactionssuch as pain or redness.Other side effects may includehypersensitivity reactions. Galcanezumab was developed byEli Lilly.It was approved for medical use in the United States and in the European Union in 2018,becoming the thirdcalcitonin gene-related peptide(CGRP) inhibitor to be approved by the USFood and Drug Administration(FDA).